Does Saccharomyces Boulardii Help With S. boulardii shows moderate evidence as an adjunct therap...?

Evidence Summary

S. boulardii shows moderate evidence as an adjunct therapy for reducing recurrence of Clostridioides difficile infection (CDI) when combined with vancomycin — global cure rate 96.6% vs 85.3% placebo, recurrence 1.7% vs 13.1% (PMID: 40457042). It also demonstrates benefit in reducing adverse events and potentially improving eradication effectiveness when added to H. pylori concomitant therapy in real-world European practice (PMID: 41923280). In combination with smectite for pediatric acute gastroenteritis, a meta-analysis of 57 RCTs found improved outcomes (PMID: 41798274), and it showed benefit for SIBO eradication when combined with rifaximin (PMID: 40884341).

Source: auto-research

Effective Dose

250-500 mg daily (clinical trials); No universally established dose across all indications